Literature DB >> 17674036

Lymphatic vessels are present in phosphaturic mesenchymal tumours.

K Williams1, A Flanagan, A Folpe, R Thakker, N A Athanasou.   

Abstract

Oncogenic osteomalacia (OO) is an acquired form of hypophosphataemic osteomalacia, which is associated most commonly with the development of a benign phosphaturic mesenchymal tumour mixed connective tissue type (PMTMCT). PMTMCTs are generally well vascularised tumours, and many have in the past been classified as haemangiomas and haemangiopericytomas. Although these tumours show some morphological variation, it has been proposed that they represent a distinct histopathological entity. Our aim in this study was to determine by immunohistochemistry the vascular profile of PMTMCT. Using monoclonal antibodies directed against several vascular markers, including the lymphatic endothelial cell antigens LYVE 1 and podoplanin, we found that PMTMCTs, in contrast to haemangiomas and haemangiopericytomas, contain lymphatic vessels. Taken with previous observations that PMTMCTs overexpress FGF23 and other gene products, this finding provides further evidence that most osteomalacia associated mesenchymal tumours represent a discrete pathological entity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674036     DOI: 10.1007/s00428-007-0471-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

1.  Late onset oncogenic osteomalacia-associated with neurofibromatosis type II.

Authors:  Y S Haviv; J Silver
Journal:  Clin Nephrol       Date:  2000-11       Impact factor: 0.975

2.  Endothelial cell phenotypic diversity. In situ demonstration of immunologic and enzymatic heterogeneity that correlates with specific morphologic subtypes.

Authors:  R R Turner; J H Beckstead; R A Warnke; G S Wood
Journal:  Am J Clin Pathol       Date:  1987-05       Impact factor: 2.493

3.  Oncogenic osteomalacia.

Authors:  G E Cotton
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

4.  Albright's syndrome associated with a soft-tissue myxoma and hypophosphataemic osteomalacia. Report of a case and review of the literature.

Authors:  E G Lever; K W Pettingale
Journal:  J Bone Joint Surg Br       Date:  1983-11

5.  Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ.

Authors:  B Sauter; D Foedinger; B Sterniczky; K Wolff; K Rappersberger
Journal:  J Histochem Cytochem       Date:  1998-02       Impact factor: 2.479

6.  Neoplastic pathology of oncogenic osteomalacia/rickets.

Authors:  N Weidner; R S Bar; D Weiss; M P Strottmann
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

7.  Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.

Authors:  Yasuhiro Takeuchi; Hisanori Suzuki; Sayoko Ogura; Rie Imai; Yuji Yamazaki; Takeyoshi Yamashita; Yoshinari Miyamoto; Hiroshi Okazaki; Kozo Nakamura; Kazuhiko Nakahara; Seiji Fukumoto; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

8.  Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions.

Authors:  L C Aschinberg; L M Solomon; P M Zeis; P Justice; I M Rosenthal
Journal:  J Pediatr       Date:  1977-07       Impact factor: 4.406

9.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

10.  Immunohistochemical differentiation between lymphangiographically verified lymphatic vessels and blood vessels.

Authors:  B M Hultberg; H Svanholm
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989
View more
  7 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  Phosphaturic mesenchymal tumor: two contrasting cases.

Authors:  Monica C Koplas; Brian P Rubin; Murali Sundaram
Journal:  Skeletal Radiol       Date:  2014-01-09       Impact factor: 2.199

3.  Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Yuichi Takashi; Nobuaki Ito; Seiji Fukumoto; Masashi Fukuyama
Journal:  Med Mol Morphol       Date:  2015-06-30       Impact factor: 2.309

5.  Phosphaturic mesenchymal tumour mixed connective tissue variant: report of three cases with unusual histological findings.

Authors:  David A Shustik; David Ce Ng; Kesavan Sittampalam
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 6.  Phosphaturic mesenchymal tumour of the sinonasal area: case report and review of the literature.

Authors:  Pavel Komínek; Ivo Stárek; Marie Geierová; Petr Matoušek; Karol Zeleník
Journal:  Head Neck Oncol       Date:  2011-03-16

Review 7.  Phosphaturic mesenchymal tumor and related wound problem.

Authors:  Xian Xiao; Xiaofang Sun; Pengwen Ni; Yao Huang; Ting Xie
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.